Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

70 results about "Critical factors" patented technology

Coal seam anti-reflection experiment device based on high-voltage electric pulse

InactiveCN104061014ADetermine the impactDetermine the scopeFluid removalGas removalElectrical impulseEngineering
The invention relates to a device for performing experiments by combining high-voltage pulse discharging and the traditional coal seam anti-reflection technology, in particular to a coal seam anti-reflection experiment device based on high-voltage electric pulse. The coal seam anti-reflection experiment device based on high-voltage electric pulse comprises a high-voltage pulse power supply, a first tube body, a second tube body, a third tube body, a rigid triaxial pressure chamber, a pressure testing pump, a hydraulic control system and a sound reflection preamplifier, wherein the first tube body, the second tube body and the third tube body are connected in sequence. The traditional hydraulic fracturing technology is simulated in the rigid triaxial pressure chamber, the high-voltage pulse power supply supplies power to a discharging electrode, therefore, the positions around a through hole of a coal sample fracture, a fracturing positions and an expanding process of the fractures in the coal sample are monitored all the time, critical factors affecting fracture development of the coal sample and state transformation of gas, an actuating range and effect laws of pulse discharging on fracture development can be obtained through the later CT scanning and electron microscopy observation results, and a theoretical foundation is provided for practical application of high-voltage pulse discharging into underground coal seam anti-reflection.
Owner:TAIYUAN UNIV OF TECH

Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Hepatocellular Carcinoma Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Hepatocellular Carcinoma Compositions Comprising the Same

Protein transduction exploits the ability of some cell-penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic CPPs, named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD), are able to deliver biologically active proteins into a variety of cells and tissues. Various cargo proteins fused to these CPPs have been used to test the functional and/or therapeutic efficacy of protein transduction. For example, recombinant proteins consisting of suppressor of cytokine signaling 3 protein (CP-SOCS3) fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. However, CP-SOCS3 fusion proteins expressed in bacteria were hard to purify in soluble form. To address these critical limitations, CPP sequences called advanced MTDs (aMTD) have been developed in this art. This is accomplished by (i) analyzing previous developed hydrophobic CPP sequences to identify specific critical factors (CFs) that affect intracellular delivery potential and (ii) constructing artificial aMTD sequences satisfied for each critical factor. In addition, solubilization domains (SDs) have been incorporated into the aMTD-fused SOCS3 recombinant proteins to enhance solubility with corresponding increases in protein yield and cell-/tissue-permeability. These recombinant SOCS3 proteins fused to aMTD/SD having much higher solubility/yield and cell-/tissue-permeability have been named as improved cell-permeable SOCS3 (iCP-SOCS3) proteins. Previously developed CP-SOCS3 proteins fused to MTM were only tested or used as anti-inflammatory agents to treat acute liver injury. In the present art, iCP-SOCS3 proteins have been tested for use as anti-cancer agents in the treatment of hepatocellular carcinoma. Since SOCS3 is frequently deleted in and loss of SOCS3 in hepatocytes promotes resistance to apoptosis and proliferation, we reasoned that iCP-SOCS3 could be used as a protein-based intracellular replacement therapy for the treatment of hepatocellular carcinoma. The results support this reasoning: treatment of hepatocellular carcinoma cells with iCP-SOCS3 results in reduced cancer cell viability, enhanced apoptosis and loss of cell migration/invasion potential. Furthermore, iCP-SOCS3 inhibits the growth of hepatocellular carcinoma in a subcutaneous xenografts model. In the present invention with iCP-SOCS3 fused to an empirically determined combination of newly developed aMTD and customized SD, macromolecule intracellular transduction technology (MITT) enabled by the advanced MTD may provide novel protein therapy against hepatocellular carcinoma.
Owner:CELLIVERY THERAPEUTICS

Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same

In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance. Protein transduction exploits the ability of some cell-penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic CPPs—named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD)—are able to deliver biologically active proteins into a variety of cells and tissues. Various cargo proteins fused to these CPPs have been used to test the functional and/or therapeutic efficacy of protein transduction. Previously, recombinant proteins consisting of suppressor of cytokine signaling 3 (SOSC3) fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. However, this SOCS3 fusion proteins expressed in bacteria cells were hard to be purified in soluble form. To address these critical limitations, CPP sequences called advanced MTDs (aMTDs) have been developed in this art. The development of this art has been accomplished by (i) analyzing previous developed hydrophobic CPP sequences to identify specific critical factors (CFs) that affect intracellular delivery potential and (ii) constructing artificial aMTD sequences that satisfy each critical factor. Furthermore, solubilization domains (SDs) have been incorporated into the aMTD-fused SOCS3 recombinant proteins to enhance solubility with corresponding increases in protein yield and cell-/tissue-permeability. These recombinant SOCS3 proteins fused to aMTD/SD having much higher solubility/yield and cell-/tissue-permeability have been named as improved cell-permeable SOCS3 (iCP-SOCS3) proteins. Previously developed SOCS3 recombinant proteins fused to MTM were only tested or used as anti-inflammatory agents to treat acute liver injury. In the present art, iCP-SOCS3 proteins have been tested for use as anti-angiogenic agents. Since SOCS3 is known to be an endogenous inhibitor of pathological angiogenesis, we reasoned that iCP-SOCS3 could be used as a protein-based intracellular replacement therapy for inhibiting angiogenesis in tumor cells. The results demonstrated in this art support this following reasoning: Cancer treatment with iCP-SOCS3 results in reduced endothelial cell viability, loss of cell migration potential and suppressed vascular sprouting potentials. In the present invention with iCP-SOCS3, where SOCS3 is fused to an empirically determined combination of newly developed aMTD and customized SD, macromolecule intracellular transduction technology (MITT) enabled by the advanced MTDs may provide novel protein therapy against cancer cell-mediated angiogenesis.
Owner:CELLIVERY THERAPEUTICS

Method and system for the discovery and description of business endeavours

A key ingredient in the design and development of enterprise software systems is a precise description of the business endeavour. In practice the engineering designs for corporate systems are surprisingly poorly articulated due to the difficulty organisations face in clearly defining their business needs in a structured and unambiguous manner. One problem is that the notations used in business process specifications are technical in nature, notoriously complex and not particularly intelligible to business stakeholders. Further, since the business environment is highly dynamic, static documentation is quickly out-of-date and rarely reusable beyond the lifespan of any particular project. There is a constant disconnect between the fluid, evolving nature of business strategies and the brittle, rigid nature of process automation. As a consequence, business stakeholders have little direct control over the structure, behaviour and governance of information systems, which is a major contributing factor in the pervasive issue of system inflexibility and adaptability. This invention provides a method and corresponding system design for addressing these limitations by articulating a business endeavour in a comprehensive, structured conceptual model that is independent of underlying technology and responsive to the dynamics of business strategy.
Owner:ROACH TERENCE MALCOLM

Performance evaluation method and device for system smoothness and terminal

ActiveCN106528389ADetermine true abilityDetermine persistenceHardware monitoringThird partyCritical factors
The invention relates to a performance evaluation method and device for system smoothness and a terminal. The method comprises the following steps: monitoring a running state of each service in a running process of a service of each serialized scene of a system, wherein the serialized scene is a scene in which a use habit of a user is simulated, and at least one third-party application is provided in the scene; acquiring abnormal state information in the running state of each service; determining exception occurring times corresponding to each piece of abnormal state information; and determining a smoothness score of the system according to the exception occurring times corresponding to each piece of abnormal state information. Through adoption of the performance evaluation method and device, each scene is monitored from the aspect of the user to obtain a measurement quantization value, and an evaluation index is obtained specific to most critical factors influencing each scene to give a smoothness score of the terminal under a certain configuration and a certain version, so that the actual capability and sustainability of the system smoothness can be determined according to the smoothness score; the user can be assisted in selecting equipment; and the defects of a software version and a hardware version are overcome.
Owner:BEIJING XIAOMI MOBILE SOFTWARE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products